FTC Stretched Standards In Enforcement Against Bayer Probiotic Claim
This article was originally published in The Tan Sheet
Executive Summary
Judge Jose Linares states in his opinion that FTC’s requirement for “competent and reliable scientific evidence” to substantiate ad claims for consumer health care products aligns with FDA’s regulation of supplement claims under DSHEA, and Bayer complied with both agencies’ regs.
You may also be interested in...
Clinical Trials Recommended For Pamprin Botanicals PMS Claims After Challenge By Bayer
Focus Consumer Healthcare appeals NAD recommendation to pull or modify majority of express and implied claims on Pamprin Botanical product packaging, in advertising and Amazon listings challenged by Bayer Consumer.
Natural Health Group Asks How ‘FTC Justified’ Requiring Clinical Trials For Health Claims
ANH asks for information “to investigate concerns that the FTC’s recent guidance will have the effect of limiting consumer access to vital scientific information about the benefits” of natural products. Litigation challenging guidance could follow the group’s review of information FTC provides.
Does FTC Health Ads Guide Read Like Rulemaking, Ignore Court Decisions On Requiring RCTs?
“I'm not sure they shouldn’t have done a notice of proposed rulemaking,” says attorney Claudia Lewis. From previous guidance, “the FTC has taken it a step in the different direction that you need robust scientific evidence, in their mind robust scientific evidence means clinical data.”